Abstract 424P
Background
Radiotherapy is a primary or an adjuvant treatment for most brain tumor patients for better tumors control and prolong survival [1]. However, cranial irradiation may cause damages to hippocampus (plural: hippocampi), which may induce dementia after they recovered from the disease [2]. To minimise radiation dose to hippocampus becomes a new trend in radiation therapy [3], [4]. This study is to investigate whether traditional coplanar VMAT (CO-VMAT) or proposed non-coplanar VMAT (NC-VMAT) is dosimetrically superior for brain tumor radiotherapy treatment in view of hippocampus sparing.
Methods
Both CO-VMAT plan and NC-VMAT plan were generated for 16 brain tumor patients (Glioblastoma: 11, Meningioma: 5) using Varian Eclipse planning system version 15.6. The prescription was to give 54 Gy to PTV in 30 fractions. Dose constraints applied for plan optimization were benchmarked against Radiation Therapy Oncology Group (RTOG). In the CO-VMAT plans, there were 1 full arc (179°-181°) and 2 half arcs. The couch angle for all arcs were 0°. For cases with PTV located at the left side of the brain, the gantry angle for the 2 half arcs were set from 0°to 179° and 179° to 0°. While for cases with PTV on the right side of the brain, the gantry angle of the 2 half arcs were set from 0° to 181°and 181°to 0°. In the NC-VMAT plans, all setting were the same as CO-VMAT plans, except that the couch angle for the 2 half arcs was at 315° for PTV located at the left side of the brain, and 45° for PTV located on the right side of the brain.
Results
Homogeneity index, conformation number, dose to other organs at risk and ipsilateral hippocampus were similar in CO-VMAT and NC-VMAT plans. The maximum dose (D-MaxCH) received by contralateral hippocampus in NC-VMAT is 4Gy lower (p=0.049) than that of the CO-VMAT. The dose received by 40 % of the contralateral hippocampus (D40%CH) in NC-VMAT is 1.46Gy (p=0.003) lower than that of the CO-VMAT. The mean D-MaxCH and mean D40%CH were reduced by 23% and 23.5% respectively in NC-VMAT plans when compared with CO-VMAT.
Conclusions
The NC-VMAT is able to minimize radiation dose to contralateral hippocampus while maintaining good plan quality. The NC-VMAT approach may help to consolidate the development of a new standard of care for brain tumor patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tung Wah College.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session